Product Description: Droxinostat (NS 41080) is a histone deacetylase (HDAC) inhibitor. Droxinostat selectively inhibits HDAC3, HDAC6, and HDAC8 with IC50 values of 16.9 μM, 2.47 μM, and 1.46 μM, respectively. Droxinostat can be used for the research of hepatocellular carcinoma (HCC)[1][2].
Applications: Cancer-programmed cell death
Formula: C11H14ClNO3
References: [1]Liu J, et al. Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP. Transl Oncol. 2016 Feb;9(1):70-8./[2]Wood TE et al. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9(1):246-56.
CAS Number: 99873-43-5
Molecular Weight: 243.69
Compound Purity: 98.91
Research Area: Cancer
Solubility: DMSO : ≥ 150 mg/mL
Target: Apoptosis;HDAC